Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2019 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq: CBIO), today announced it has entered into a global license and collaboration agreement with Biogen...
December 09, 2019 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Presents Two Posters on MarzAA at the 61st Annual American Society of Hematology Conference

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and...
November 12, 2019 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at the Stifel Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst...
November 07, 2019 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports Third Quarter 2019 Operating & Financial Results and Provides a Corporate Update

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended September 30,...
November 06, 2019 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Poster Presentations at the 61st Annual American Society of Hematology Conference

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel medicines to address hematology...
October 03, 2019 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Provides DalcA Phase 2b Trial Update

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today provided an update on enrollment in its Phase 2b study of dalcinonacog alfa (DalcA), a...
September 26, 2019 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at the Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst...
September 05, 2019 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at the 2019 ASBMB Symposium on Serine Proteases in Pericellular Proteolysis and Signaling Conference

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral presentation at the 2019 American Society for Biochemistry and...
August 29, 2019 16:55 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Transition of Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that its chief financial officer, Fletcher Payne, will be stepping down from...
August 16, 2019 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at the 2019 Hemophilia Drug Development Summit

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral presentation at the Second Annual 2019 Hemophilia Drug Development...